Diabetic polyneuropathy treatment by benfotiamine.

[Article in Russian]

Sadekov RA, Danilov AB, Vein AM.

2nd Department of Internal Medicine,
 Municipal St. John's Hospital, 
Budapest, Hungary.
Arzneimittelforschung. 1999 Mar;49(3):220-4. 

Abstract

Efficiency of benfothiamine was studied in treatment of diabetic polyneuropathy in 14 patients with diabetes mellitus type II (1 dragee 3 times a day, within 6 weeks). After the course of treatment the intensity of pains was decreased according to visual analogous scale on the average from 8.2 to 2.3 scores, the indices of vibratory sensitivity improved significantly as well as the data of cardiovascular tests characterizing parasympathetic control of heart rhythm. Meanwhile latent periods of the evoked sympathetic potentials on arms and legs which were initially lengthened became significantly shorter. A clear-cut tendency was also found to increasing conduction rate for excitation through the motor nerves. The treatment resulted in the improvement of the condition in 93% of the cases. The conclusion was made about efficiency and safety of benfothiamine application in therapy of patients with diabetic polyneuropathy.

  | Home |  to order  |
 

  1.   Benfotiamine  prevents diabetic side effects
  2.   Benfotiamine  a new approach to preventing diabetic retinopathy
  3.   Benfotiamine  delays formation of advanced glycosylation end-products
  4.   Benfotiamine  effectiveness in diabetic neuropathy 
  5.   Benfotiamine  efficacy in diabetic polyneuropathy 
  6.   Benfotiamine  efficacy in patients diabetic neuropathy
  7.   Benfotiamine  bioavailability 
  8.   Benfotiamine  treatment of diabetic polyneuropathy 
  9.   Benfotiamine  is indicated in end-stage renal disease 
10.   Benfotiamine  may prevent diabetic complications
11.   Benfotiamine  inhibits formation of advanced glycation end products
12.   Benfotiamine  suppressed the formation of advanced glycation end products

 

 

 

 

 

Hit Counter